company background image
MRNS * logo

Marinus Pharmaceuticals BMV:MRNS * Stock Report

Last Price

Mex$5.25

Market Cap

Mex$254.8m

7D

-9.5%

1Y

n/a

Updated

22 Dec, 2024

Data

Company Financials +

Marinus Pharmaceuticals, Inc.

BMV:MRNS * Stock Report

Market Cap: Mex$254.8m

MRNS * Stock Overview

A pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. More details

MRNS * fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Marinus Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Marinus Pharmaceuticals
Historical stock prices
Current Share PriceUS$5.25
52 Week HighUS$124.00
52 Week LowUS$5.25
Beta1.19
1 Month Change-25.00%
3 Month Changen/a
1 Year Changen/a
3 Year Change-97.81%
5 Year Change-95.33%
Change since IPO-99.19%

Recent News & Updates

Recent updates

Shareholder Returns

MRNS *MX PharmaceuticalsMX Market
7D-9.5%-3.4%-2.9%
1Yn/a-27.4%-14.0%

Return vs Industry: Insufficient data to determine how MRNS * performed against the MX Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how MRNS * performed against the MX Market.

Price Volatility

Is MRNS *'s price volatile compared to industry and market?
MRNS * volatility
MRNS * Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.6%
Market Average Movement4.1%
10% most volatile stocks in MX Market6.0%
10% least volatile stocks in MX Market2.6%

Stable Share Price: MRNS *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine MRNS *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003166Scott Braunsteinmarinuspharma.com

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.

Marinus Pharmaceuticals, Inc. Fundamentals Summary

How do Marinus Pharmaceuticals's earnings and revenue compare to its market cap?
MRNS * fundamental statistics
Market capMex$254.79m
Earnings (TTM)-Mex$2.82b
Revenue (TTM)Mex$631.63m

0.4x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MRNS * income statement (TTM)
RevenueUS$31.47m
Cost of RevenueUS$102.78m
Gross Profit-US$71.31m
Other ExpensesUS$69.18m
Earnings-US$140.49m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.55
Gross Margin-226.64%
Net Profit Margin-446.49%
Debt/Equity Ratio-141.4%

How did MRNS * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:10
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Marinus Pharmaceuticals, Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
François BriseboisCraig-Hallum Capital Group LLC
Jason KolbertD. Boral Capital LLC.